The Ohio EPA says Hikma Pharmaceuticals in Columbus sent a 275-gallon tote containing a cleaning chemical to a facility not authorized to dispose of it.

Fitch has upgraded Hikma Pharmaceuticals to a 'BBB' rating with a stable outlook, reflecting its improved financial and operational performance.

In April, Hikma said it expected revenue to grow by 4% to 6% in 2025 and for core operating profit to be in the range of USD730 million to USD770 million, would be growth of 4.3% at the mid-point.

London, 15 May 2025 – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, is today hosting sell-side analysts and investors at its US manufacturing and R&D facility in ...

Hikma Pharmaceuticals has agreed to pay $50 million to settle a class action accusing the drugmaker of scheming to delay a generic version of Jazz’s blockbuster narcolepsy drug Xyrem, causing ...

Hikma reiterates full year guidance following good start to the year . London, 24 April 2025 – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an ...

With Hikma’s strong market presence and commercial capabilities, this collaboration represents an excellent strategic synergy." Mekinist had a market value of approximately $436 million in the ...

Hikma buys rights to FDA-approved cancer treatment trametinib, a generic version of Novartis' (NVS) Mekinist, with 180 days of U.S. market exclusivity. Read more here.

Hikma Executive Vice Chairperson and President of MENA Mazen Darwazah said: "We are pleased to add rucaparib, an innovative oncology treatment, to our growing oncology portfolio in MENA.” “This ...

Hikma Pharmaceuticals PLC HIK shares slipped 1.68% to £19.86 Monday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100 Index UKX falling 0.10% to ...

Riad Mishlawi, Hikma’s chief executive, said the impact of the new class of drugs had a comparable impact to the first antibiotic penicillin. “It’s not only because of the weight loss . . .

AMMAN — Hikma Pharmaceuticals PLC posted 'robust' financial results for 2024, with revenue climbing 9 per cent to $3.127 billion compared to $2.875 billion in 2023, according to audited figures ...